Zoetis - ZTS Stock Forecast, Price & News

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Analyst Ratings Changes

Several equities research analysts have issued reports on ZTS shares. StockNews.com downgraded Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, April 26th. The Goldman Sachs Group cut their price objective on Zoetis from $208.00 to $202.00 and set a "buy" rating for the company in a report on Thursday, July 21st. Stifel Nicolaus decreased their target price on Zoetis from $275.00 to $225.00 and set a "buy" rating on the stock in a report on Friday, June 24th. William Blair restated an "outperform" rating on shares of Zoetis in a research note on Friday, August 5th. Finally, Piper Sandler initiated coverage on shares of Zoetis in a research note on Monday, July 11th. They issued an "overweight" rating and a $205.00 price objective on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $224.14.

Zoetis Trading Down 1.5 %

Shares of Zoetis stock opened at $171.79 on Wednesday. The company has a market cap of $80.42 billion, a price-to-earnings ratio of 38.95, a PEG ratio of 3.00 and a beta of 0.73. Zoetis has a 12-month low of $154.18 and a 12-month high of $249.27. The company's 50-day moving average price is $172.13 and its 200-day moving average price is $180.11. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14.

Zoetis (NYSE:ZTS - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by ($0.02). The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a return on equity of 49.03% and a net margin of 26.14%. Zoetis's revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.19 earnings per share. On average, equities analysts expect that Zoetis will post 5.01 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be given a dividend of $0.325 per share. This represents a $1.30 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend is Wednesday, July 20th. Zoetis's payout ratio is currently 29.48%.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction on Monday, June 27th. The stock was sold at an average price of $175.00, for a total transaction of $758,450.00. Following the sale, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,145,225. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Willie M. Reed sold 1,855 shares of Zoetis stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $162.31, for a total value of $301,085.05. Following the transaction, the director now owns 6,782 shares of the company's stock, valued at approximately $1,100,786.42. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total transaction of $758,450.00. Following the sale, the executive vice president now directly owns 23,687 shares of the company's stock, valued at approximately $4,145,225. The disclosure for this sale can be found here. Insiders sold 18,356 shares of company stock valued at $3,250,158 in the last 90 days. Insiders own 0.12% of the company's stock.